- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07725393
Adjunctive Subgingival Pomegranate Peel Extract Gel for Stage II-III Periodontitis (POME-PERIO)
Adjunctive Subgingival Pomegranate Peel Extract Gel for Stage II-III Periodontitis: A Randomized Split-Mouth Trial
This randomized, triple-blind, placebo-controlled split-mouth clinical trial aims to evaluate the clinical and biochemical efficacy of subgingival pomegranate peel extract gel as an adjunct to scaling and root planing (SRP) in the treatment of Stage II-III periodontitis.
Thirty-two participants diagnosed with Stage II-III periodontitis will receive SRP in all selected periodontal sites. Test sites will receive locally delivered pomegranate peel extract gel, while contralateral control sites will receive a placebo gel. Clinical periodontal parameters, including probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), bleeding on probing (BOP), and gingival crevicular fluid levels of matrix metalloproteinase-8 (MMP-8), will be assessed at baseline, 1 month, 3 months, and 6 months to evaluate whether adjunctive pomegranate peel extract gel improves periodontal healing compared with SRP alone.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Gehad Samy, BDS, MSc, PhD
- Numéro de téléphone: +201092710515
- E-mail: gehadasaad.26@azhar.edu.eg
Lieux d'étude
-
-
Cairo Governorate
-
Cairo, Cairo Governorate, Egypte
- Recrutement
- Faculty of Dental Medicine for Girls, Al-Azhar University
-
Contact:
- Gehad Samy, BDS, MSc, PhD
- Numéro de téléphone: +201092710515
- E-mail: gehadasaad.26@azhar.edu.eg
-
Chercheur principal:
- Gehad Samy, BDS, MSc, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
- Adults aged 30 to 60 years.
- Systemically healthy individuals.
- Diagnosis of Stage II or Stage III periodontitis according to the 2018 Classification of Periodontal and Peri-Implant Diseases and Conditions.
- Presence of at least 20 natural teeth.
- Presence of at least two non-adjacent periodontal pockets (≥5 mm) located in different quadrants suitable for split-mouth allocation.
- Clinical attachment loss consistent with Stage II or Stage III periodontitis.
- Ability and willingness to comply with the study protocol and attend all follow-up visits.
- Provision of written informed consent.
Exclusion Criteria:
- Current smokers or users of any tobacco products.
- Pregnant or lactating women.
- Patients with systemic diseases known to affect periodontal status or wound healing (e.g., uncontrolled diabetes mellitus, immunodeficiency disorders, osteoporosis requiring antiresorptive therapy).
- Use of systemic antibiotics, corticosteroids, immunosuppressive agents, or non-steroidal anti-inflammatory drugs within the previous 3 months.
- Periodontal therapy received within the previous 6 months.
- History of allergy or hypersensitivity to pomegranate or any component of the study materials.
- Orthodontic treatment during the study period.
- Participation in another clinical trial within the previous 6 months.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Pomegranate Peel Extract Gel
Periodontal sites receive scaling and root planing followed by subgingival application of pomegranate peel extract gel.
|
Locally delivered subgingival gel containing pomegranate peel extract administered after scaling and root planing.
|
|
Comparateur placebo: Placebo Gel
Periodontal sites receive scaling and root planing followed by subgingival application of placebo gel with identical appearance and consistency.
|
Placebo gel without active ingredient, identical in appearance and consistency to the experimental gel, administered after scaling and root planing.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Probing Pocket Depth (PPD)
Délai: Baseline, 1 month, 3 months, and 6 months
|
Change in probing pocket depth (PPD), measured in millimeters using a calibrated periodontal probe at the selected periodontal sites.
|
Baseline, 1 month, 3 months, and 6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Clinical Attachment Level (CAL)
Délai: Baseline, 1 month, 3 months, and 6 months
|
Change in clinical attachment level (CAL), measured in millimeters using a calibrated periodontal probe at the selected periodontal sites.
|
Baseline, 1 month, 3 months, and 6 months
|
|
Change in Plaque Index (PI)
Délai: Baseline, 1 month, 3 months, and 6 months
|
Change in plaque index (PI) assessed using the Silness and Löe Plaque Index.
|
Baseline, 1 month, 3 months, and 6 months
|
|
Change in Gingival Index (GI)
Délai: Baseline, 1 month, 3 months, and 6 months
|
Change in gingival index (GI) assessed using the Löe and Silness Gingival Index.
|
Baseline, 1 month, 3 months, and 6 months
|
|
Change in Bleeding on Probing (BOP)
Délai: Baseline, 1 month, 3 months, and 6 months
|
Change in bleeding on probing (BOP), assessed as the presence or absence of bleeding following gentle periodontal probing.
|
Baseline, 1 month, 3 months, and 6 months
|
|
Change in Gingival Crevicular Fluid Matrix Metalloproteinase-8 (MMP-8) Levels
Délai: Baseline, 1 month, 3 months, and 6 months
|
Change in gingival crevicular fluid matrix metalloproteinase-8 (MMP-8) concentration measured using enzyme-linked immunosorbent assay (ELISA).
|
Baseline, 1 month, 3 months, and 6 months
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Luchian I, Goriuc A, Sandu D, Covasa M. The Role of Matrix Metalloproteinases (MMP-8, MMP-9, MMP-13) in Periodontal and Peri-Implant Pathological Processes. Int J Mol Sci. 2022 Feb 4;23(3):1806. doi: 10.3390/ijms23031806.
- Tyagi P, Dodwad V, Kukreja BJ, Kukreja P. A comparison of the efficacy of scaling and root planning with application of pomegranate chip, pomegranate gel, and scaling and root planing in sufferers with adult periodontitis - A prospective study. J Indian Soc Periodontol. 2021 Jan-Feb;25(1):41-46. doi: 10.4103/jisp.jisp_243_20. Epub 2021 Jan 7.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- P-PD-26-09
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .